Individual susceptibility to cancer may result from several host factors including differences in metabolism, DNA In human lung cancer, p53 mutations (both the mutation pattern and frequency) have been linked with tobacco smoking; the type of mutation most frequently observed is G:C to T:A transversion, a mutation preferentially induced by benzo[alpyrene diol epoxide. An association between the presence of this transversion and the genotype deficient in glutathione S-transferase Mi-mediated detoxification has been observed in lung cancer. Taken together, these findings suggest that determination of metabolic at risk genotypes in combination with levels of DNA adducts in target (surrogate) tissues and the p53 mutation pattern should allow the identification of susceptible individuals and subgroups in carcinogen-exposed populations.
Cancer Susceptibility in Environmental Carcinogenesis
Epidemiological studies have estimated that up to 80 to 90% of all cancers are related to environmental factors, tobacco smoke, and diet (1) . Tobacco use is unquestionably a major causative factor, accounting for about 30% of all cancer cases worldwide, especially lung cancer which is presently the most common malignancy in the world. Individual susceptibility to cancer may result from several host factors including differences in metabolism, DNA repair, altered expression of protooncogenes and tumor suppressor genes, and nutritional status ( Figure 1 ) (2 Many of the polymorphic genes of carcinogen metabolism show considerable ethnic differences in gene structure and allelic distribution (e.g., rare alleles, gene amplifications, and pseudogenes). Many of the first reports on genetic risk modification were from Japan, and only after several studies among various Caucasian populations has an estimate of allele frequencies, and thus of risk genotypes, been obtained. Remarkable variation in metabolic phenotypes and genotypes has been reported for different ethnic and geographic populations (3) (4) (5) (6) (7) (8) (14) .
The formation of smoking-related DNA adducts in human lung tissue may be a good dosimetric exposure marker. Smokers have significantly elevated levels of aromatic or hydrophobic adducts compared with nonsmokers (15) (16) (17) (Table 1) . In some cases it is evident that adduct levels are linearly related to total smoking exposure (15, 16) but, in the case of lung cancer patients only, the shorter the period of smoking before cancer occurred, the higher the adduct level (17) NNK-derived DNA adducts have only partially been characterized (19) . In humans, the balance between toxification and detoxification of NNK may be influenced by the individual's enzymatic capacity. By measuring a urinary metabolite of NNK, NNAL glucuronide, the latter could possibly serve as an index of an individual's activation/detoxification capacity. Because glucuronidation may exert genetic polymorphism (20) , some smokers with higher glucuronidation capacity measurable by the ratio of NNAL glucuronide/ NNAL may partially be protected against the carcinogenicity of NNK.
Endogenous Adducts
The exocyclic DNA adducts ethenodeoxyadenine and ethenodeoxycytosine have been found to be formed by the human carcinogen vinyl chloride and by urethane; they also can be formed from lipid peroxidation products such as trans-4-hydroxy-2-nonenal via epoxidation (21) (22) (23) . Etheno adducts thus may serve as a DNA marker of oxidative stress. After development of a highly specific and ultrasensitive assay, these etheno adducts can now be detected with the sensitivity of 4 adducts/1010 normal nucleotides (24) . Recently, a close correlation has been observed between aliphatic epoxide-induced sister chromatid exchanges (SCEs) in cultured human lymphocytes and GSTT1 polymorphism. The null genotype had higher induced, as well as background, frequencies of SCEs (25, 26) . Because mutagenic epoxides produced from lipid peroxidation products could be substrates for GSTTI (27) , but this discovery was challenged later (28) . Thus the association between the mutant CYPIAI alleles and CYPlAl functional activity is not clear at the moment, but recent studies indicate that variant alleles at the MspI site in exon 7 could result in a more active CYP lAl enzyme (29, 30) . A significant correlation in a Japanese population between susceptibility to lung cancer and homozygosity for the rare MspI allele was reported by Kawajiri et al. (31) and Nakachi et al. (32) . Another closely linked polymorphism, a point mutation resulting in an amino acid substitution (Ile-Val) in the heme-binding region of the CYPlAl protein was found by Hayashi et al. (33) . This genotype results in an altered enzyme activity and was shown to be associated with squamous cell and small cell types of lung cancer (34) . There are significant ethnic differences in the frequency of CYPIAI alleles, and both the m2 and Val alleles appear to be rare in Caucasians (5, 35, 36) . This requires more follow-up studies involving more cancer patients and controls to unmask the association in Caucasians.
CYPJA2
The CYP1A2 isoform is predominantly expressed in liver and it activates a large number of dietary and environmental procarcinogens. This isoform is expressed in all studied human livers. To date, no genetic polymorphism has been found, but phenotypic polymorphism has been demonstrated using caffeine as a probe drug (37) . CYP246
In humans, CYP2A6 isoforms are mediators of 7-hydroxylation of coumarin, a component of cigarette smoke, certain alcoholic beverages, and a common constituent of various plants. CYP2A6 is also known to be capable of activating several other nitrosamines present in tobacco smoke and in the diet. The CYP2A gene cluster has been recently characterized (38) (43) . Therefore, the distribution of the different alleles in lung cancer patients and controls should be investigated. CYP3A5, which is polymorphically expressed in the liver, has been found in human lungs (44) .
AhR and Arnt Genes
The induction of CYPlAl is initiated by the specific binding of PAH compounds to a soluble intracellular protein, the aromatic hydrocarbon receptor (AhR) (45) . Hankinson (49) .
The genetic polymorphism of the GSTM1 gene that encodes the glutathione S-transferase M1 enzyme is a result of a homozygous deletion of the entire GSTM1 gene locus (50) . The GSTM1 gene locus contains three alleles, i.e., the GSTMIA and GSTMIB alleles, which differ by a single amino acid, and a deficient GSTMI null allele. About 50% of the Caucasian population inherits two deficient alleles (i.e., they are homozygous for the null allele of the gene) and are thus devoid of GSTM1 activity. The GSTMI null genotype frequency has been reported to show marked ethnic variation (51) . Individuals lacking GSTM1 could be at a greater risk for developing lung cancer due to deficient detoxification processes; this notion is supported by recent studies (52) . In persons who lack the GSTM1 gene, activation of carcinogens in tobacco smoke (e.g., B[a]P) appears to be increased, while the efficacy of detoxification is limited both qualitatively (absence of GSTM1-1 enzyme and low expression of GSTM3-3 enzyme) and quantitatively (low overall GST activity). This was confirmed by biochemical studies ( Table 1 ). The metabolic activity (AHH activity, level of bulky PAH-DNA adducts in lung parenchyma) was measured in Finnish lung cancer patients divided according to their smoking habits and GSTM1 genotype (9) . AHH activity was highest in smokers, independent of the GSTM1 genotype; also, the amount of DNA adducts was highest in smokers (Table 1) . When smokers and ex-smokers were grouped according to GSTMI gene status, smokers with a nulled GSTM1 gene had about 10% more bulky PAH-DNA adducts in lung parenchyma, whereas ex-smokers with this gene defect had a 2.4-fold excess of these DNA lesions. An independent study (17) also reported an excess of individuals with GSTMI deficiency with high adduct levels in their lung tissue among male lung cancer patients. In our study (Table 1) , one other parameter was determined: cytochrome P4501A2-catalyzed activity measurable in the urine by the use of caffeine as a probe drug (53 The first epidemiological studies appeared to confirm a relationship between GSTMI deficiency and lung cancer risk (54, 55) . There are, however, several putative confounding factors that are known to affect the phenotype such as environmental exposures, nutrition, and differences in smoking habits (56) . In recent genotyping studies using PCR assays (51) , no association has been found between null genotype and lung adenocarcinoma, but a tendency for an association between the GSTMI genotype and squamous cell carcinoma has been reported (57) (58) (59) . GSTT1 Recently a GST null phenotype unrelated to the GSTMI was described for the glutathione-dependent detoxification of naturally occurring monohalomethanes. In human erythrocytes the monohalomethanes are detoxified by conjugation with glutathione (60) (61) (62) . About 60 to 80% of the human population is able to carry out this metabolic reaction, whereas the remainder is unable to do so (61) . Further characterization of this phenotype showed that glutathione conjugation of the industrially used chemicals dichloromethane and ethylene oxide (which is also a metabolic product of ethylene in animals and humans) could only be catalyzed by blood samples from the conjugator population (63) . However, positive conjugator status is not necessarily beneficial because conjugation of monohalomethanes and ethylene oxide is detoxifying, whereas conjugation of dichloromethane yields a mutagenic metabolite (64 (66, 67) . Substrates for the enzyme include epoxides of environmental toxins such as the carcinogenic PAHs, aromatic amines, and benzene (67) (68) (69) . Frequently, the metabolism of epoxide-containing compounds by mEH results in the production of inherently less reactive and less toxic intermediates (66, 70) . However, in certain instances, notably in concert with oxidative metabolism by the cytochrome P450s, hydrolysis of particular PAH epoxides by mEH can lead to the formation of highly electrophilic and mutagenic diol epoxides (67, 69 (72) . Recently, there has been considerable progress in the molecular genetics of this enzyme family (73) . Nine human cDNAs have been cloned to date, and they have been classified into two families, UGT1 and UGT2, on the basis of the similarity of their deduced amino acid sequences (74) . Evidence for variability in the general population has been obtained, but no genetic polymorphism of the UGT genes has so far been observed (75) . The data based on phenotyping analysis of NNK metabolites, NNAL and NNAL glucuronides, in the urine of smokers suggest the presence of polymorphism in UGT (20) . (79, 80) . In human lung cancer, p53 mutations (both the mutation pattern and frequency) have been linked with tobacco smoking (78, (81) (82) (83) . The type of mutation most frequently observed in lung cancer is G:C to T:A transversion (80), a type of mutation preferentially induced in experimental systems by (+)-anti-B[a]P diol epoxide. Furthermore, an association between the genotype deficient in GSTM1-mediated detoxification and presence of G:C to T:A transversions has been observed in lung cancer patients (78) . These findings suggest that investigation of p53 mutation patterns in relation to metabolic at-risk genotypes and levels of DNA adducts in lung tissue will provide valuable information for understanding mechanisms of pulmonary carcinogenesis.
Susceptible Genotypes and Genetic Alterations in Lung Cancer
Alterations in microsatellite sequences (simple sequence repeats) of the human genome were originally observed in sporadic and hereditary forms of colon cancer (84, 85) . Since the discovery, a variety of human tumors including small cell and non-small cell lung cancer have been found to contain similar instability of microsatellite sequences (86) (87) (88) (97) , and this may represent a feasible alternative approach to identify chromosomal locations of lung cancer susceptibility genes in humans. Genetic linkage studies have constituted an important approach to study the genetics of diseases through the identification of the number and chromosomal location of loci affecting a disease (98, 99) . The chromosomal mapping of a disease loci allowed the subsequent cloning of disease genes whose germ-line mutations cause inherited predisposition to common tumor types (colon carcinoma, breast cancer, etc.). Thus, genetic linkage studies in lung cancer pairs of siblings and of second degree relatives may facilitate finding the chromosomal location of loci affecting inherited predisposition to lung cancer.
Perspectives
Recent knowledge of the genetic basis for individual metabolic variation has opened new possibilities for studies focusing on increased individual susceptibility to environmentally induced cancer, and the development of simple PCR-based assays has enabled the identification of an individual's genotype for a variety of metabolic polymorphisms. Cancer susceptibility due to chemical exposure is likely to be determined by an individual's phenotype for a number of enzymes, both activating and detoxifying, relevant to that of a single carcinogen or mixtures of carcinogens. Given the number and variability in expression of carcinogen-metabolizing enzymes and the complexity of chemical exposures, assessment of a single polymorphic enzyme (genotype) may not be sufficient, and the establishment of a risk profile for each individual or subgroup seems to be required. Mutations in the p53 gene are among the most common genetic changes in human cancer. The frequency and type of p53 mutations can act as a fingerprint of carcinogen exposure and may therefore provide information on external etiological agents, intensity of exposure, and host factors affecting the tumorigenesis process. Given the rapid advances in methodology, the determination of metabolic at-risk genotypes in combination with levels of DNA adducts in target (surrogate) tissues and p53 mutation patterns should allow identification of susceptible individuals/ subgroups in carcinogen-exposed populations. Once identified, these high-risk subjects might be persuaded more easily to stop their (smoking) habits or to avoid hazardous exposure, or in the case of smokers, it might be possible to offer an intensive or personalized smoking cessation program.
